Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

瑋俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

POSITIVE PROFIT ALERT AND CONTINUED SUSPENSION OF TRADING

This announcement is made by Wai Chun Bio-Technology Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 22 September 2026, 2 October 2026, 7 October 2026, 28 October 2026 and 4 November 2026 (the "**Announcements**") in relation to, among other things, the delay in publication of the 2026 Annual Results and the postponement of the board meeting for the purpose of, among other matters, approving the 2026 Annual Results and considering the payment of a final dividend, if any. Unless otherwise defined or the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

POSITIVE PROFIT ALERT

The Board wishes to inform the Shareholders and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 30 June 2026 (the "**Year**"), the Group is expected to record a profit of not less than HK$30.0 million as compared to the net loss of approximately HK$10.7 million for the year ended 30 June 2025. The expected turnaround from loss to profit for the Year is primarily contributed by a one-off reversal of impairment losses on property, plant and equipment of approximately HK$52.1 million in view of the significant improvement of actual operating performance and outlook of the manufacturing and sale of modified starch cash generating unit, which was partially offset by reversal of deferred tax assets of approximately HK$15.0 million.

The Company is still in the process of finalising the annual results of the Group for the Year, the information contained in this announcement is only a preliminary assessment by the Board based on the latest information currently available, which has not been audited or reviewed by the Company's independent auditors or the audit committee, and may be subject to change. The 2026 Annual Results of the Group is expected to be published on 13 November 2026.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company on the Stock Exchange has been suspended since 9:00 a.m. on 2 October 2026 and will remain suspended pending the publication of the 2026 Annual Results.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Wai Chun Bio-Technology Limited
Lam Ka Chun
Chairman and Executive Director

Hong Kong, 11 November 2026

As at the date of this announcement, the Board comprises:

Executive Director:
Mr. Lam Ka Chun *(Chairman and Chief Executive Officer)*

Independent Non-executive Directors:
Mr. Wong Po Keung
Mr. Wang Ziniu
Ms. Xu Huiling